푹스각막내피이영양증(FECD) - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• The total Fuchs Endothelial Corneal Dystrophy market size of in the 7MM in 2023 was approximately ~USD 858 million, this is anticipated to grow by 2036.
• The US accounts for the largest market size of Fuchs Endothelial Corneal Dystrophy in 2023, i.e. nearly USD 394 million, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.
• According to DelveInsight's estimates, between EU4 and the UK, Germany accounted for the largest market of Fuchs Endothelial Corneal Dystrophy with nearly USD 88 million in 2023, followed by Italy with nearly USD 67 million in the respective year, while Spain accounted for the least with around USD 50 million.
• The Fuchs Endothelial Corneal Dystrophy market is projected to witness consistent growth throughout the forecast period (2026-2036). The market size of FECD in the 7MM is expected to increase, driven by the launch of emerging therapies.
• As per DelveInsight analysis, in 2025, the total diagnosed prevalent cases of FECD in the 7MM were approximately 19.3 million. These cases are projected to increase further during the study period (2022-2036).
• The total market size of the Fuchs Endothelial Corneal Dystrophy treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Ripasudil/K-321, TTHX1114/NM141, and others.

DelveInsight's "Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the FECD, historical and forecasted epidemiology and the FECD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Fuchs Endothelial Corneal Dystrophy market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM FECD market size from 2022 to 2036. The report also covers current FECD treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Fuchs Endothelial Corneal Dystrophy Treatment Market

Fuchs Endothelial Corneal Dystrophy is a progressive hereditary disease affecting the cornea's endothelial layer. It is characterized by corneal edema, guttae formation, reduced visual acuity, and can lead to corneal blindness. FECD is more common in women, and its prevalence varies geographically in the 7MM. FECD is associated with genetic factors, with mutations in genes like COL8A2, SLC4A11, TCF4, and ZEB1 implicated in its development.

Fuchs Endothelial Corneal Dystrophy Diagnosis

Diagnosis of FECD involves clinical examination, in vivo imaging, and laboratory examination of removed corneas. Currently, slit lamp examination, specular microscopy, corneal thickness measurement, and confocal microscopy are used to identify FECD. There is a huge unmet medical need to improve the sensitivity of testing in the early stages. Although various tools are developed to improve disease diagnosis at an early stage such as deep learning algorithms and techniques like Scheimpflug tomography and anterior segment optical coherence tomography (AS-OCT), there is still a need to improve the availability and accessibility of these image analysis tools for early detection, monitoring of disease progression, and customized therapeutic interventions.

Fuchs Endothelial Corneal Dystrophy Treatment

Medical management of early FECD is limited to decreasing corneal edema with topical sodium chloride 5% drops, hypertonic saline drops, and solutions (ophtasyloxane) or ointments to shorten the morning edema and facilitate corneal dehydration. Phototherapeutic keratectomy, amniotic membrane transplants, anterior stromal puncture, and conjunctival flaps are also used to relieve painful symptoms, especially those associated with ruptured bullae in the later stages of the disease. Even cycloplegic, antibiotic ointment and patching are prescribed to treat ruptured corneal bullae. If a persistent or large epithelial defect is there, then bandage contact lenses are recommended.

However, these treatments do not have any curative effect because they do not act on the cause of the disease, which is the dysfunction of the endothelial layer. Frequency of usage has no effect; it only provides temporary relief and does not change the course of the disease; also, there is a stinging associated with these agents, which reduces acceptance.

Fuchs Endothelial Corneal Dystrophy Epidemiology

As the market is derived using the patient-based model, the Fuchs Endothelial Corneal Dystrophy epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of FECD, Gender-specific Cases of FECD, Age-specific Cases of FECD, and Grade-specific Cases of FECD in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2022 to 2036.

• As per DelveInsight analysis, in 2025, the total diagnosed prevalent cases of FECD in the 7MM were approximately 19.3 million. These cases are projected to increase further during the study period (2022-2036).
• In 2025, the United States accounted for the highest proportion of diagnosed prevalent cases of FECD (approximately 6.6 million) throughout the 7MM. This was followed by Japan, with about 3.2 million cases. Spain on the other hand accounted for the lowest cases (approximately 1.4 million).
• There is a higher prevalence among females across the 7MM. Specifically, in the US in 2025, approximately 6 million cases among males and 10.8 million cases among females were accounted, indicating a female predominance.

Fuchs Endothelial Corneal Dystrophy Drug Chapters

The drug chapter segment of the FECD report encloses a detailed analysis of FECD marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands FECD clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Fuchs Endothelial Corneal Dystrophy Emerging Drugs

Ripasudil (K-321): Kowa Pharmaceuticals

It is a rho-kinase inhibitor that lowers intraocular pressure (IOP) by increasing conventional aqueous outflow. Rho-associated protein kinase (ROCK) is a protein that regulates the shape and movement of cells in several tissues, including the eye. ROCK inhibitors lower IOP by depolymerizing intracellular actin in the conventional outflow tissues: the Trabecular Meshwork (TM) and Schlemm's canal (SC). Furthermore, ROCK inhibitors suppress extracellular matrix production by TM cells, representing a potential alternative to lowering IOP. The drug is currently in Phase III of clinical development for the treatment of Fuchs endothelial corneal dystrophy (FECD).

TTHX 1114: Trefoil Therapeutics

TTHX1114 is a proprietary engineered fibroblast growth factor-1 [FGF-1 (eFGF-1)] variant designed to protect corneal endothelial cells from stress and injury and restore vision loss by stimulating cell proliferation and migration. Trefoil has received extensive in-kind development support for TTHX1114's use from the NIH through its Therapeutics for Rare and Neglected Diseases Program. Trefoil Therapeutics announced positive Phase II (STORM) trial results for TTHX1114 showing corneal regeneration and vision recovery following DSO surgery. Trefoil is also developing a topical formulation of TTHX1114 which stimulates corneal epithelial cell growth, potentially reducing common complications associated with ulcerative corneal conditions, such as pain, inflammation, and loss of vision due to corneal scarring.

STN1010904/AE-001 (sirolimus): (Santen/ActualEyes)

STN1010904, also known as sirolimus or AE-001, which is being developed by Santen Pharmaceutical along with ActualEyes, is an ophthalmic suspension for the treatment of FECD. It is a sirolimus eye drop that is an mTOR inhibitor, that suppresses the formulation of collagenous excrescences (guttae) on the surface of the corneal endothelial layer and the apoptosis of endothelial cells in FECD. It suppresses corneal edema, thereby maintaining the cornea's transparency and visual acuity. Santen Pharmaceuticals is co-developing the drug with ActualEyes to ensure early market introduction, treat FECD patients, and improve their QoL. It is currently being evaluated in Phase IIa of clinical trials.

Fuchs Endothelial Corneal Dystrophy Market Outlook

FECD has a diverse treatment classification associated with the disease landscape. The management of FECD primarily revolves around the utilization of hyperosmotic sodium chloride, steroids, and others as needed.

Standard of care (Hyperosmotic sodium chloride, Steroids, etc.) is the major revenue generator in the current treatment landscape.

• The total market size of Fuchs Endothelial Corneal Dystrophy in the 7MM in 2023 was approximately USD 858 million, this is anticipated to grow by 2036.
• Increasing awareness about Fuchs Endothelial Corneal Dystrophy may increase market size in the coming years, resulting in an increase in the prevalence of FECD patients.
• The US accounts for the largest market size of Fuchs Endothelial Corneal Dystrophy in 2023, i.e. nearly USD 394 million, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.
• According to DelveInsight's estimates, between EU4 and the UK, Germany accounted for the largest market of Fuchs Endothelial Corneal Dystrophy with nearly USD 88 million in 2023, followed by Italy with nearly USD 67 million in the respective year, while Spain accounted for the least with around USD 50 million.
• The total market size of Fuchs Endothelial Corneal Dystrophy in Japan was nearly USD 132 million in 2023, which is expected to increase by 2036.

Fuchs Endothelial Corneal Dystrophy Drugs Uptake

• This section focuses on the uptake rate of potential drugs expected to launch in the market during 2022-2036. For example, TTHX1114/ NM141 in the US is expected to be launched by 2025.

Fuchs Endothelial Corneal Dystrophy Pipeline Development Activities

The report provides insights into Fuchs Endothelial Corneal Dystrophy clinical trials within Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for FECD emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on FECD evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Jules Stein Eye Institute/UCLA, Los Angeles, Fight for Sight, New York, Department of Pharmacology and Biochemistry, UT Southwestern Medical Center, Texas, Philadelphia Eye Associates and Wills Eye Hospital, Philadelphia, Eye Center, Faculty of Medicine, University of Freiburg, Freiburg, Moorfields Eye Hospital, London, Kyoto Prefectural University of Medicine, Kyoto, and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or FECD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Fuchs Endothelial Corneal Dystrophy Market Report

• The report covers a segment of key events, an executive summary, descriptive overview of Fuchs Endothelial Corneal Dystrophy, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Fuchs Endothelial Corneal Dystrophy market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Fuchs Endothelial Corneal Dystrophy market.

Fuchs Endothelial Corneal Dystrophy Report Insights

• FECD Patient Population
• FECD Therapeutic Approaches
• FECD Pipeline Analysis
• FECD Market Size and Trends
• Existing and Future Market Opportunity

Fuchs Endothelial Corneal Dystrophy Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Fuchs Endothelial Corneal Dystrophy Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• FECD Drugs Uptake
• Key FECD Market Forecast Assumptions

Fuchs Endothelial Corneal Dystrophy Report Assessment

• Current FECD Treatment Practices
• FECD Unmet Needs
• FECD Pipeline Product Profiles
• FECD Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• FECD Market Drivers
• FECD Market Barriers

Key Questions Answered In The FECD Market Report:

Fuchs Endothelial Corneal Dystrophy Market Insights

• What was the Fuchs Endothelial Corneal Dystrophy total market size, the market size by therapies, and market share (%) distribution in 2022, and how would it all look in 2036? What are the contributing factors for this growth?
• What unmet needs are associated with the current treatment market of Fuchs Endothelial Corneal Dystrophy?
• What are the patents of emerging therapies for Fuchs Endothelial Corneal Dystrophy?
• Which drug is going to be the largest contributor by 2036?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Fuchs Endothelial Corneal Dystrophy Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Fuchs Endothelial Corneal Dystrophy? What will be the growth opportunities across the 7MM concerning the patient population of Fuchs Endothelial Corneal Dystrophy?
• What is the historical and forecasted Fuchs Endothelial Corneal Dystrophy patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for Fuchs Endothelial Corneal Dystrophy and why?
• What factors are affecting the diagnosis of the indication?

Current Fuchs Endothelial Corneal Dystrophy Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating Fuchs Endothelial Corneal Dystrophy? What are the current guidelines for treating Fuchs Endothelial Corneal Dystrophy in the US and Europe?
• How many companies are developing therapies for treating Fuchs Endothelial Corneal Dystrophy?
• How many emerging therapies are in the mid-stage and late stage of development for treating Fuchs Endothelial Corneal Dystrophy?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Fuchs Endothelial Corneal Dystrophy?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted markets of Fuchs Endothelial Corneal Dystrophy?

Reasons to Buy FECD Market Forecast Report

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Fuchs Endothelial Corneal Dystrophy Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1 Key Insights

2 Report Introduction

3 FECD Market Overview at a Glance

• 3.1 Market Share (percent) Distribution of FECD in 2022
• 3.2 Market Share (percent) Distribution of FECD in 2036

4 Methodology of FECD Epidemiology and Market

5 Executive Summary of FECD

6 Key Events

7 Disease Background and Overview

• 7.1 Introduction
• 7.2 Types of Corneal Dystrophies
• 7.3 Clinical Manifestations
• 7.4 Signs and Symptoms
• 7.5 Risk Factors
• 7.6 Genetics and Inheritance
• 7.7 Pathogenesis
• 7.8 Prognosis
• 7.9 Staging
• 7.10 Diagnosis
  • 7.10.1 Diagnostic criteria
  • 7.10.2 Differential diagnosis
• 7.11 Treatment and Management

8 Epidemiology and Patient Population

• 8.1 Key Findings
• 8.2 Assumptions and Rationale: The 7MM
  • 8.2.1 Total Diagnosed Prevalent Cases of FECD
  • 8.2.2 Gender-specific Cases of FECD
  • 8.2.3 Age-specific Cases of FECD
  • 8.2.4 Grade-specific Cases of FECD
• 8.3 Total Diagnosed Prevalent Cases of FECD in the 7MM
• 8.4 The US
  • 8.4.1 Total Diagnosed Prevalent Cases of FECD in the US
  • 8.4.2 Gender-specific Cases of FECD in the US
  • 8.4.3 Age-specific Cases of FECD in the US
  • 8.4.4 Grade-specific Cases of FECD in the US
• 8.5 The EU4 and the UK
  • 8.5.1 Total Diagnosed Prevalent Cases of FECD in the EU4 and the UK
  • 8.5.2 Gender-specific Cases of FECD in the EU4 and the UK
  • 8.5.3 Age-specific Cases of FECD in the EU4 and the UK
  • 8.5.4 Grade-specific Cases of FECD in the EU4 and the UK
• 8.6 Japan
  • 8.6.1 Total Diagnosed Prevalent Cases of FECD in Japan
  • 8.6.2 Gender-specific Cases of FECD in Japan
  • 8.6.3 Age-specific Cases of FECD in Japan
  • 8.6.4 Grade-specific Cases of FECD in Japan

9 Patient Journey

10 Emerging Drugs

• 10.1 Key Cross Competition
• 10.2 Ripasudil (K-321): Kowa Pharmaceuticals
  • 10.2.1 Drug description
  • 10.2.2 Other development activities
  • 10.2.3 Clinical development
  • 10.2.4 Clinical trials information
  • 10.2.5 Product profile
  • 10.2.6 Analysts' views
• 10.3 TTHX 1114: Trefoil Therapeutics
  • 10.3.1 Drug description
  • 10.3.2 Other development activities
  • 10.3.3 Clinical development
  • 10.3.4 Clinical trials information
  • 10.3.5 Safety and efficacy
  • 10.3.6 Product profile
  • 10.3.7 Analysts' Views

11 FECD: Market Analysis

• 11.1 Key Findings
• 11.2 Key Market Forecast Assumptions
• 11.3 Market Outlook
• 11.4 Conjoint Analysis
• 11.5 Market Size of FECD in 7MM
• 11.6 Market Size of FECD by Therapies in the 7MM
• 11.7 Market Size of FECD in the US
  • 11.7.1 Total Market Size of FECD
  • 11.7.2 Market Size of FECD by Therapies
• 11.8 Market Size of FECD in the EU4 and the UK
  • 11.8.1 Germany
    • 11.8.1.1 Total Market Size of FECD
    • 11.8.1.2 Market Size of FECD by Therapies
  • 11.8.2 France
    • 11.8.2.1 Total Market Size of FECD
    • 11.8.2.2 Market Size of FECD by Therapies
  • 11.8.3 Italy
    • 11.8.3.1 Total Market Size of FECD
    • 11.8.3.2 Market Size of FECD by Therapies
  • 11.8.4 Spain
    • 11.8.4.1 Total Market Size of FECD
    • 11.8.4.2 Market Size of FECD by Therapies
  • 11.8.5 The UK
    • 11.8.5.1 Total Market Size of FECD
    • 11.8.5.2 Market Size of FECD by Therapies
• 11.9 Market Size of FECD in Japan
  • 11.9.1 Total Market Size of FECD
  • 11.9.2 Market Size of FECD by Therapies

12 KOL Views

13 SWOT Analysis

14 Unmet Needs

15 Market Access

• 15.1 The United States
  • 15.1.1 CMS
• 15.2 The EU4 and the UK
  • 15.2.1 Germany
  • 15.2.2 France
  • 15.2.3 Italy
  • 15.2.4 Spain
  • 15.2.5 The United Kingdom
• 15.3 Japan
  • 15.3.1 MHLW

16 Appendix

• 16.1 Bibliography
• 16.2 Acronyms and Abbreviations
• 16.3 Report Methodology

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight